AbCellera Results Presentation Deck

2020 BUSINESS UPDATE. HIGHLIGHTS ~400K PATIENTS TREATED 72% INCREASE IN # OF PARTNERSHIPS $233M IN REVENUE Proved tech & business model Strengthened competitive advantage Positioned for growth with strong liquidity AbCellera COVID-19 program with Eli Lilly brings bamlanivimab into clinical trials 90 days after initiation. Bamlanivimab authorized in 15 countries. Expanded technology stack with acquisitions OrthoMabTM and Trianni. Secured $126 million for CMC and GMP manufacturing capabilities. $594 million in cash and $212 million in accounts receivable at year end. COPYRIGHT ABCELLERA 3

View entire presentation